MAPT and Alzheimer disease: Furthermore, plasma P‐tau217 and P‐tau181 identified AD co‐pathology in patients with DLB or PDD by predicting both tau‐PET positivity and CSF Aβ positivity with a relatively high accuracy (AUC 0.78–0.88).